Elite in B-Cell Lymphoma

Dr. Stefan K. Barta

Hematology
Penn Medicine
Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
On Staff At
Accepting New Patients
Offers Telehealth
25 Years of Experience
Elite in B-Cell Lymphoma
Penn Medicine
Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stefan Barta is a Hematologist in Philadelphia, Pennsylvania. Dr. Barta has been practicing medicine for over 25 years and is rated as an Elite provider by MediFind in the treatment of B-Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, T-Cell Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Barta is currently accepting new patients.

His clinical research consists of co-authoring 146 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 52 articles and participated in 8 clinical trials in the study of B-Cell Lymphoma.

Graduate Institution
Johann Wolfgang Goethe University
Residency
Whipps Cross University Hospital
Specialties
Hematology
Licenses
Internal Medicine in PA
Board Certifications
Hematology, 2010
Medical Oncology, 2010
Fellowships
The St. Bartholomew's and The Royal London
Montefiore Medical Center
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Pennsylvania Hospital
Penn Presbyterian Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Abramson Cancer Center Perelman 4th Floor West
3400 Civic Center Boulevard, West Pavilion, 4th Floor, Philadelphia, PA 19104
Call: 215-615-5858

Additional Areas of Focus

Dr. Barta has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Burkitt Lymphoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Other, Drug
Study Drug: Nelfinavir Mesylate
Study Phase: Phase 2
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma
A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Alisertib, Bortezomib, Rituximab
Study Phase: Phase 1
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
Enrollment Status: Suspended
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drugs: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral Azacitidine
Study Phase: Phase 2
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Vinblastine
Study Phase: Phase 1/Phase 2
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
A Phase I Trial Assessing the Feasibility of Romidepsin Combined With Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-cell Lymphoma
A Phase I Trial Assessing the Feasibility of Romidepsin Combined With Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-cell Lymphoma
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drugs: Romidepsin, Brentuximab vedotin
Study Phase: Phase 1
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 07, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase I Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Phase I Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Enrollment Status: Completed
Publish Date: August 24, 2022
Intervention Type: Drug
Study Drugs: Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride
Study Phase: Phase 1
A Phase I/II Study to Determine Feasibility and Safety MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
A Phase I/II Study to Determine Feasibility and Safety MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: July 08, 2022
Intervention Type: Drug
Study Drugs: MK-3475, Copanlisib
Study Phase: Phase 1/Phase 2
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: May 19, 2021
Intervention Type: Drug
Study Drugs: Decitabine, Carboplatin, Arsenic Trioxide
Study Phase: Phase 2
Phase 1 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma
Phase 1 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma
Enrollment Status: Completed
Publish Date: May 06, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of the Deglycosylated Ricin A Chain-containing Combined Anti-CD19 and Anti-CD22 Immunotoxin Combotox in Combination With High-Dose Cytarabine in Adult Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia
A Phase 1 Study of the Deglycosylated Ricin A Chain-containing Combined Anti-CD19 and Anti-CD22 Immunotoxin Combotox in Combination With High-Dose Cytarabine in Adult Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: September 06, 2019
Intervention Type: Other, Biological, Drug
Study Phase: Phase 1
View 14 Less Clinical Trials

146 Total Publications

Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study.
Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study.
Journal: Research square
Published: November 19, 2025
View All 146 Publications
Similar Doctors
Elite in B-Cell Lymphoma
Dr. Stephen J. Schuster
Hematology
Elite in B-Cell Lymphoma
Dr. Stephen J. Schuster
Hematology

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Schuster is a Hematologist in Philadelphia, Pennsylvania. Dr. Schuster is rated as an Elite provider by MediFind in the treatment of B-Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in B-Cell Lymphoma
Dr. Daniel J. Landsburg
Hematology
Elite in B-Cell Lymphoma
Dr. Daniel J. Landsburg
Hematology

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Landsburg is a Hematologist in Philadelphia, Pennsylvania. Dr. Landsburg is rated as an Elite provider by MediFind in the treatment of B-Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Landsburg is currently accepting new patients.

Elite in B-Cell Lymphoma
Dr. Sunita D. Nasta
Hematology
Elite in B-Cell Lymphoma
Dr. Sunita D. Nasta
Hematology

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sunita Nasta is a Hematologist in Philadelphia, Pennsylvania. Dr. Nasta is rated as an Elite provider by MediFind in the treatment of B-Cell Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Nasta is currently accepting new patients.

VIEW MORE B-CELL LYMPHOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barta's expertise for a condition
ConditionClose
  • Elite
  • B-Cell Lymphoma
    Dr. Barta is
    Elite
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Mantle Cell Lymphoma (MCL)
    Dr. Barta is
    Elite
    . Learn about Mantle Cell Lymphoma (MCL).
    See more Mantle Cell Lymphoma (MCL) experts
  • Marginal Zone Lymphoma (MZL)
    Dr. Barta is
    Elite
    . Learn about Marginal Zone Lymphoma (MZL).
    See more Marginal Zone Lymphoma (MZL) experts
  • Non-Hodgkin Lymphoma
    Dr. Barta is
    Elite
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
  • T-Cell Lymphoma
    Dr. Barta is
    Elite
    . Learn about T-Cell Lymphoma.
    See more T-Cell Lymphoma experts
  • Distinguished
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Barta is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Barta is
    Distinguished
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Anaplastic Large Cell Lymphoma
    Dr. Barta is
    Distinguished
    . Learn about Anaplastic Large Cell Lymphoma.
    See more Anaplastic Large Cell Lymphoma experts
  • Classical Hodgkin Lymphoma
    Dr. Barta is
    Distinguished
    . Learn about Classical Hodgkin Lymphoma.
    See more Classical Hodgkin Lymphoma experts
  • Cutaneous T-Cell Lymphoma (CTCL)
    Dr. Barta is
    Distinguished
    . Learn about Cutaneous T-Cell Lymphoma (CTCL).
    See more Cutaneous T-Cell Lymphoma (CTCL) experts
  • Diffuse Large B-Cell Lymphoma (DLBCL)
    Dr. Barta is
    Distinguished
    . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
    See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
View All 14 Distinguished Conditions
  • Advanced
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Barta is
    Advanced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Adult T-Cell Leukemia
    Dr. Barta is
    Advanced
    . Learn about Adult T-Cell Leukemia.
    See more Adult T-Cell Leukemia experts
  • Angioimmunoblastic T-cell Lymphoma
    Dr. Barta is
    Advanced
    . Learn about Angioimmunoblastic T-cell Lymphoma.
    See more Angioimmunoblastic T-cell Lymphoma experts
  • Bone Marrow Transplant
    Dr. Barta is
    Advanced
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Burkitt Lymphoma
    Dr. Barta is
    Advanced
    . Learn about Burkitt Lymphoma.
    See more Burkitt Lymphoma experts
  • Childhood Acute Myeloid Leukemia
    Dr. Barta is
    Advanced
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
View All 16 Advanced Conditions
  • Experienced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Barta is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Adult Immune Thrombocytopenia
    Dr. Barta is
    Experienced
    . Learn about Adult Immune Thrombocytopenia.
    See more Adult Immune Thrombocytopenia experts
  • Agranulocytosis
    Dr. Barta is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Aleukemic Leukemia Cutis (ALC)
    Dr. Barta is
    Experienced
    . Learn about Aleukemic Leukemia Cutis (ALC).
    See more Aleukemic Leukemia Cutis (ALC) experts
  • Anemia
    Dr. Barta is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
  • Aplastic Anemia
    Dr. Barta is
    Experienced
    . Learn about Aplastic Anemia.
    See more Aplastic Anemia experts
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Close
      0 / 1000

      Please provide us with the below insurance information:

              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.